FZ
Therapeutic Areas
IDEAYA Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Darovasertib (IDE196) | Uveal Melanoma (GNAQ/GNA11 mutations) | Phase 2/3 |
| IDE397 | MTAP-deleted Solid Tumors | Phase 1/2 |
| IDE161 | HRD (Homologous Recombination Deficient) Solid Tumors | Phase 1 |
| IDE849 | DLL3-upregulated Solid Tumors (SCLC, NETs, NECs, Melanoma) | Phase 1 |
| IDE705 | HRD Solid Tumors | Preclinical |
| IDE275 | Undisclosed Synthetic Lethality Indication | Preclinical |
Leadership Team at IDEAYA Biosciences
YS
Yujiro S. Hata
President and Chief Executive Officer, Founder
DM
Darrin M. Beaupre, M.D., Ph.D.
Chief Medical Officer
MW
Michael White, Ph.D.
Chief Scientific Officer
T(
Theodora (Theo) Ross, M.D., Ph.D.
Chief Development Officer
JB
Joshua Bleharski, Ph.D.
Chief Financial Officer
SD
Stu Dorman
Chief Commercial Officer
DB
Douglas B. Snyder
Chief Legal Officer
DA
Daniel A. Simon
Chief Business Officer
PA
Paul A. Barsanti, Ph.D.
Chief Technology Officer
AR
Andres Ruiz Briseno
Chief Accounting Officer